Jun 8 2016
Insilico Medicine, a big data analytics company situated at the Emerging Technology Centers at the Eastern campus of Johns Hopkins University in Baltimore, focuses on using advanced deep learning techniques for drug and biomarker discovery. Life Extension, an organization set up in the early 1980s in Florida, is committed to increasing the health and longevity of humans.
Insilico Medicine and Life Extension have now formed an exclusive collaboration focused on discovering innovative biomarkers of human aging by using artificial intelligence and big data analytics. They also aim to identify nutrient formulation to promote health and longevity. Insilico Medicine is planning to apply deep learning algorithms and next-generation signaling pathway activation analysis methods to identify nutraceuticals that imitate the tissue-specific transcriptional factors of several known interventions and pathways linked to health and longevity. The collaborative team will also look for dietary ingredients "geroprotectors" that imitate the young healthy signaling status in tissues of older human. Life Extension will make use of these details to develop new nutraceutical products to promote health and longevity.
For many years I was buying a range of supplements from Life Extension, and saw how passionate they are about extending healthy human life and supporting cutting-edge research in the field. Life Extension's Discovery Research and Product Development Teams have decades of experience in the pharmaceutical and nutraceutical research and have set very high standards for science based nutraceutical discovery. I am very excited to have the opportunity to collaborate with Life Extension in order to expand our research activities substantially and translate our knowledge to healthy beneficial products.
Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. and the Chief Science Officer of the Biogerontology Research Foundation in the UK.
Insilico Medicine recently published a number of key papers on using deep learning methods to biomedical applications in prominent peer-reviewed journals including:
"Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data" and "Applications of Deep Learning in Biomedicine" in Molecular Pharmaceutics, a journal published by the American Chemical Society
"Deep biomarkers of human aging: Application of deep neural networks to biomarker development" in Aging, a high-impact journal in aging research
Insilico Medicine investigators frequently publish papers on different aspects of aging, longevity as well as geroprotector discovery. "Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic" was recently published in Aging Cell, another leading journal in the field.
We believe accelerating the rate of progress in novel biomarker identification, as well as precision nutrient formulation development is critical. We are excited about our collaboration with Insilico Medicine because of their outstanding academic publication record, proven ability in deep learning, and team of scientists dedicated to extending productive human longevity. Our staff looks forward to collaborating with the scientists at Insilico Medicine in order to utilize their cutting edge technology to stay at the forefront of aging and natural medicine research.
Andrew G. Swick, Ph.D. Senior Vice President of Scientific Affairs, Discovery Research and Product Development at Life Extension.
Life Extension’s goal is to improve the health and longevity of humans by engaging in industry and academic collaborations and bringing in experienced researchers. Artificial intelligence is a promising area, where unique results can be achieved by combining years of experience in the nutraceutical field with high-performance computing and advanced biologically-inspired algorithms.